Feasibility study for a new industrial biotech bioprocess for the manufacture of a novel biopolymer with unique properties

Synthomer已经确定了一种产品的市场缺口，如果使用工业生物技术制造，这种产品将具有更好的性能，并且没有现有制造技术制造的类似材料的缺点。他们预计，该产品将迅速融入其主要市场领域之一，并因其改进的特性而获得市场认可。Synthomer是全球五大乳液和特种聚合物供应商之一，在这一目标市场拥有丰富的经验。Ingenza是一家生物技术推动者，使用专有技术开发新型生物工艺。Ingenza将通过创建能够用于Synthomer产品的转基因微生物来证明生物工艺的可行性。在成功完成可行性研究后，Synthomer和Ingenza希望进行持久的合作，以优化可持续的生物生产工艺，取代传统的油基合成。

Synthomer have identified a market gap for a product which if made using industrial biotechnology would have improved properties and none of the drawbacks of similar materials made by existing manufacturing technologies. They anticipate that this product would be rapidly assimilated into one of their key market areas and leverage market acceptance due the the improved characteristics. Synthomer are a top 5 global supplier of emulsion and specialty polymer company with vast experience in this target market. Ingenza are a biotechnology enabler who develop novel bioprocesses using proprietary technologies. Ingenza will demonstrate feasibility for a bioprocess by creating a genetically modified microorganism capable of being used in Synthomer's product. Following the successful completion of the Feasibility Study, Synthomer and Ingenza expect to enter into a lasting collaboration to optimise a sustainable manufacturing bioprocess to replace conventional oil based synthesis.